Election-Year Dynamics Could Derail Mental Health Reform Legislation
Meanwhile, a Senate panel faces a deadline for its medical innovation bill.
Los Angeles Times:
Despite Bipartisan Support, Mental Health Reform Bill Could Be Derailed
Mental health advocates are pressing Democrats and Republicans on Capitol Hill not to abandon a push to modernize the nation's ailing mental health system amid rising partisan tensions over President Obama's Supreme Court pick. The effort has picked up crucial bipartisan support in the Senate and galvanized dozens of groups representing patients, physicians and state and local leaders. The Obama administration has also backed calls for reform, proposing more than $500 million in new federal spending to expand mental health services nationwide. But election-year politics and uncertainty over funding are fueling concerns that years of collaborative work by lawmakers from both parties may not bear fruit. (Levey, 4/6)
Morning Consult:
Senate Health Committee Faces Deadline For Medical Innovation
The Senate faces a tight deadline if it’s going to pass a medical bill this year designed to speed drug and precision medicine developments. The legislation needs to be smoothed of kinks and on the floor within two weeks unless GOP leaders alter their overall schedule for the year. The Health, Education, Labor and Pensions Committee will hold its third and final votes on a series of small bipartisan bills on Wednesday, but there’s still no deal on the most important issue — additional funding for the National Institutes of Health and the Food and Drug Administration. (Owens, 4/5)
The Hill:
Collins: Drug Pricing Bill Not Likely At Innovation Hearing
Sen. Susan Collins (R-Maine) says that her bill aimed at fighting high profile drug price spikes will likely not be considered as part of a health committee session on Wednesday. “I don't think it's going to come up tomorrow, but I'm assured by the chairman that it will be considered at some point,” Collins said Tuesday, referring to Sen. Lamar Alexander (R-Tenn.).
The health committee is holding a markup Wednesday on the last batch of a series of innovation bills aimed at speeding up the FDA’s approval process for drugs. That package has been seen as a possible vehicle for some sort of provision related to drug prices, which have been a hot button issue on the campaign trail and elsewhere. (Sullivan, 4/5)
In other news —
The Washington Post:
VA Formally Proposes New Limits On Appeals Rights For Its Executives
Senior executives at the Department of Veterans Affairs overseeing health care programs could appeal disciplinary actions against them only through internal department channels, under a formal proposal the department has sent to Congress. While other VA executives still could bring appeals to the Merit Systems Protection Board, that adjudicatory agency would have to give more deference to the department’s decisions, under the proposal. (Yoder, 4/5)
